The “A-B-C” classification reveals outcome trajectories in patients with hepatocellular carcinoma under atezolizumab/bevacizumab

We aimed to identify subgroups of patients with unresectable hepatocellular carcinoma (HCC) using a non‐a priori, data‐driven machine learning approach to uncover subgroups with distinct profiles acro...

cghjournal.org

Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma

Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...

medrxiv.org

Cytidine diphosphate diacylglycerol synthase 2 is a synthetic lethal target in mesenchymal-like cancers - Nature Genetics

The paralogs cytidine diphosphate diacylglycerol synthase 1 and 2 form a potentially targetable synthetic lethal relationship in mesenchymal-like cancers that involves disruption of lipid metabolism.

nature.com

The pivot penalty in research - Nature

An analysis of millions of scientific papers and patents reveals a ‘pivot penalty’ when researchers shift direction, with the impact of studies decreasing rapidly the further they move from their prev...

nature.com

Utility of tumor and non-tumor biopsies during percutaneous radiofrequency ablation for hepatocellular carcinoma

We aim to assess the safety and diagnostic/prognostic value of tumor and non-tumor biopsies systematically collected during radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC).

jhep-reports.eu

Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials

Common Sense Oncology (CSO) prioritises treatments providing meaningful benefits for people with cancer. Here, we describe CSO principles aimed at improving the design, analysis, and reporting of rand...

thelancet.com

Engineered extrachromosomal oncogene amplifications promote tumorigenesis - Nature

Large extrachromosomal DNAs are engineered using a CRISPR- and Cre–loxP-based approach and shown to drive cancer in mouse models, with potential applications in determining the role of oncogene a...

nature.com